Consequently, patients with more aggressive subtypes of breast cancer, including human epidermal growth factor receptor-2 (HER2) positive and triple negative breast cancer (TNBC), are candidates for NAC according to the 2020 update of the National Comprehensive Cancer Network (NCCN) guidelines. The gene discussed is ERBB2; the disease is breast carcinoma.